PIK3R1
ENSG00000145675
Target class
Enzyme
Chromosome
5
Approved drugs
0
Clinical candidates (approved and in development)
26
- Approved drugs
- 0
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 26
- Chemical probe available
- No
- Target name
- PIK3R1
- Gene name
- Phosphoinositide-3-kinase regulatory subunit 1
- Gene symbol
- PIK3R1
- Protein name
- Phosphatidylinositol 3-kinase regulatory subunit alpha (PI3-kinase regulatory subunit alpha) (PI3K regulatory subunit alpha) (PtdIns-3-kinase regulatory subunit alpha) (Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha) (PI3-kinase subunit p85-alpha) (PtdIns-3-kinase regulatory subunit p85-alpha)
- GRB1
- p85-ALPHA
- p85
- p85alpha
- Gene biotype
- Protein coding
- Gene family
- SH2 domain containing
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 154.42
- Tissue specificity (Gini)
- 0.363
- Tissue specificity (tau)
- 0.769
- KEGG gene identifiers
- hsa:5295
- Protein interaction confidence
- 0.894281
- Protein interaction partners
- 199
- R-HSA-109704
- R-HSA-112399
- R-HSA-114604
- R-HSA-1236382
- R-HSA-1250342
- R-HSA-1257604
- R-HSA-1266695
- R-HSA-1433557
- R-HSA-1660499
- R-HSA-180292
- R-HSA-1839117
- R-HSA-186763
- R-HSA-1963642
- R-HSA-198203
- R-HSA-201556
- R-HSA-202424
- R-HSA-2029485
- R-HSA-210993
- R-HSA-2219530
- R-HSA-2424491
- R-HSA-2730905
- R-HSA-373753
- R-HSA-389357
- R-HSA-416476
- R-HSA-430116
And 53 more, listed on the interactive page.
- End position
- 68301821
- Start position
- 68215740
- Chromosome
- 5
- Strand
- Forward
- Cytosol
- Tissue specificity (tau)
- 0.769245
- Expression inequality (Gini)
- 0.363449
Expression in transcripts per million
- Nerve - Tibial
- 154.42
- Esophagus - Muscularis
- 89.53
- Esophagus - Gastroesophageal Junction
- 83.67
- Breast - Mammary Tissue
- 82.22
- Uterus
- 78.28
Expression in transcripts per million
- Nerve - Tibial154.42
- Esophagus - Muscularis89.53
- Esophagus - Gastroesophageal Junction83.67
- Breast - Mammary Tissue82.22
- Uterus78.28
- Cervix - Endocervix70.12
- Artery - Tibial65.23
- Fallopian Tube62.08
- Minor Salivary Gland61.1
- Colon - Sigmoid59.68
- Adipose - Subcutaneous59.23
- Cervix - Ectocervix58.7
- Vagina57.94
- Artery - Coronary53.98
- Brain - Frontal Cortex (BA9)53.1
- Lung45.05
- Adipose - Visceral (Omentum)43.81
- Ovary42.91
- Bladder41.4
- Skin - Sun Exposed (Lower leg)40.69
- Brain - Cortex37.6
- Cells - Cultured fibroblasts35.85
- Artery - Aorta35.5
- Skin - Not Sun Exposed (Suprapubic)35.32
- Muscle - Skeletal32.86
And 29 more, listed on the interactive page.
- GO:0000209
- GO:0019221
- GO:0032869
- GO:0033120
- GO:0034143
- GO:0034976
- GO:0035655
- GO:0042267
- GO:0042307
- GO:0043066
- GO:0043491
- GO:0045944
- GO:0048009
- GO:0048661
- GO:0050821
- GO:0060396
- GO:0061470
- GO:1900103
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0016020
- GO:0001784
- GO:0005158
- GO:0005159
- GO:0005168
- GO:0005515
- GO:0019903
- GO:0035014
- GO:0043125
- GO:0043559
Related records
Trials (197)
- 5G-PEARL: Paxalisib in Malignant Brain Tumours
- A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
- A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers
- A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
- A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer
- A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
- A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
- A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
- A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
- A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
- A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
- A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
- A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
- A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
- A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Drugs (28)
- Apitolisib PI3-kinase class I inhibitor
- AZD-6482 PI3-kinase class I inhibitor
- BGT-226 PI3-kinase class I inhibitor
- BGT-226 FREE BASE PI3-kinase class I inhibitor
- Buparlisib PI3-kinase class I inhibitor
- Dactolisib PI3-kinase class I inhibitor
- DS-7423 PI3-kinase class I inhibitor
- Gedatolisib PI3-kinase class I inhibitor
- GSK-1059615 PI3-kinase class I inhibitor
- Izorlisib PI3-kinase class I inhibitor
- Omipalisib PI3-kinase class I inhibitor
- Panulisib PI3-kinase class I inhibitor
- Paxalisib PI3-kinase class I inhibitor
- PF-04691502 PI3-kinase class I inhibitor
- Pictilisib PI3-kinase class I inhibitor
- Pilaralisib PI3-kinase class I inhibitor
- Puquitinib PI3-kinase class I inhibitor
- Puquitinib mesylate dihydrate PI3-kinase class I inhibitor
- PWT-33587 PI3-kinase class I inhibitor
- Recilisib PI3-kinase class I inhibitor